Mechanism-based CNS Disease Modeling: Applications in Neurology and Psychiatry Drug Research & Development

Mechanism-based CNS Disease Modeling: Applications in Neurology and Psychiatry Drug Research & Development

February 26, 2015 at 12 noon ET

by Hugo Geerts, PhD, Chief Scientific Officer of In Silico Biosciences, faculty at Perelman School of Medicine (University of Pennsylvania) and Drexel University Department of Pharmacology

 

 

This webinar featured Dr. Hugo Geerts, Chief Scientific Officer of In Silico Biosciences, who discussed “Mechanism-based CNS Disease Modeling: Applications in Neurology and Psychiatry Drug Research & Development.”

Dr. Geerts holds a bachelor’s degree in theoretical physics, a bachelor’s degree in medicine, a PhD in biophysics, and a master’s in pharmaceutical sciences. He has almost 20 years of experience in drug discovery and development as a research fellow at the Janssen Research Foundation, where he headed the Alzheimer discovery research. In addition to his work at In Silico Biosciences, a company that provides mechanistic disease modeling services in CNS research & development, Dr. Geerts is on the faculty of the Perelman School of Medicine (University of Pennsylvania) and the Drexel University Department of Pharmacology.

In this webinar, Dr. Geerts will discuss “mechanistic disease modeling,” which is based on mathematical models of relevant human brain circuits that are derived from well-defined physico-chemical and physiological data from preclinical models. In addition, these are parameterized with neuropathology, imaging, clinical, and genotype data from patients to which the neurophysiological effects of over 30 different neurotransmitter receptor systems have been added. Currently, the model is clinically calibrated for schizophrenia, Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. To demonstrate this work, Dr. Geerts will show examples where the model has proven to be of value in CNS research & development projects, including three blind predictions of clinical outcomes with new molecular entities (NMEs).

Orion Bionetworks is a Cambridge, MA, non-profit 501(c)(3) research organization that builds Bionetwork Alliance communities to assemble and integrate high-dimensional biomarker, biosensor, and phenotypic data and advance knowledge discovery through the power of predictive analytics and

computer modeling to accelerate the development of new diagnostics, treatments, and cures for brain disorders.

Orion’s webinar series fosters an exchange of knowledge on the latest breakthroughs in a variety of technical fields including bioinformatics, computational modeling, biomarker research, and nanotechnologies, and discusses how these can be utilized to accelerate time to cure for brain disease. We are inviting expert speakers to submit proposals for future webinars on the above topics. Each webinar is 50 minutes in length, followed by a 10-minute Q&A with questions submitted virtually by the participants. All webinars are free and open to the public.

For any questions and to submit webinar proposals, please contact our colleagues at Percolation Communications (Gloria.Dunn@percolationcom.com). We thank you in advance for helping to make this a dynamic and informative event.

 

About Hugo Geerts, PhD

OLYMPUS DIGITAL CAMERAHugo Geerts is currently Chief Scientific Officer of In Silico Biosciences, a company providing pioneering mechanistic disease modeling services in CNS R&D for pharma companies with programs in Neurology and Psychiatry. After a degree in physics and a PhD in Biophysics, a Bachelor Degree in Medicine and a Master in Pharmaceutical Sciences, he worked for 17 years with Dr. Paul Janssen, the greatest drug hunter in history at the Janssen Research Foundation (J&J) leading the Alzheimer Discovery research with programs in tangle and b-amyloid pathology and supported the successful clinical development of galantamine. He is faculty of the University of Pennsylvania Perelman School of Medicine and the Drexel University Pharmacology Department.